These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 11119944)

  • 1. Economic evaluation of therapeutic drug monitoring services in renal transplant recipients treated with cyclosporine.
    Lee KL; Peng YL; Chou JL; Lee KT; Chung HM
    Transplant Proc; 2000 Nov; 32(7):1801-6. PubMed ID: 11119944
    [No Abstract]   [Full Text] [Related]  

  • 2. Composite outcomes in renal transplantation using cyclosporine.
    Keown PA
    Transplant Proc; 2004 Mar; 36(2 Suppl):35S-39S. PubMed ID: 15041304
    [No Abstract]   [Full Text] [Related]  

  • 3. Evaluation of tolerability, safety, and efficacy of cyclosporine microemulsion in renal transplant recipients.
    Gracida C; Melchor JL; Miranda ME; Bartolano C
    Transplant Proc; 1996 Aug; 28(4):2171-3. PubMed ID: 8769191
    [No Abstract]   [Full Text] [Related]  

  • 4. Conversion of stable renal transplant recipients from Sandimmune to Sang-35, a novel cyclosporine formulation, using a dose-normalized equivalence method.
    First MR; Weiskittel P; Burton M; Shah M; Dreyer D; Fleck P; Bey C; Peddi R; Canafax D; Schroeder TJ
    Transplant Proc; 1998 Aug; 30(5):1701-5. PubMed ID: 9723249
    [No Abstract]   [Full Text] [Related]  

  • 5. Missing impact of cyclosporine on osteoporosis in renal transplant recipients.
    Grotz W; Mundinger A; Gugel B; Exner V; Reichelt A; Schollmeyer P
    Transplant Proc; 1994 Oct; 26(5):2652-3. PubMed ID: 7940828
    [No Abstract]   [Full Text] [Related]  

  • 6. Plasma endothelin in cyclosporine A-treated renal transplant patients.
    Grekas D; Bamichas G; Karamouzis M; Bacharaki D; Savidis N; Tourkantonis A
    Transplant Proc; 1999 May; 31(3):1703-5. PubMed ID: 10331044
    [No Abstract]   [Full Text] [Related]  

  • 7. Conversion from cyclosporine Sandimmune to cyclosporine Neoral in the stable renal transplant population.
    Griffin PJ; Moore RH; Jurewicz WA; Lord RH; Webley Y; Jenkins J
    Transplant Proc; 1997; 29(1-2):303. PubMed ID: 9123007
    [No Abstract]   [Full Text] [Related]  

  • 8. Quality of life in renal transplant recipients treated with cyclosporine in comparison with hemodialysis maintenance.
    Yoshimura N; Ohmori Y; Tsuji T; Oka T
    Transplant Proc; 1994 Oct; 26(5):2542-3. PubMed ID: 7940783
    [No Abstract]   [Full Text] [Related]  

  • 9. Conversion to tacrolimus immunosuppression in renal transplant recipients: 12-month follow-up.
    Citterio F; Scatà MC; Romagnoli J; Pozzetto U; Nanni G; Castagneto M
    Transplant Proc; 2002 Aug; 34(5):1685-6. PubMed ID: 12176535
    [No Abstract]   [Full Text] [Related]  

  • 10. Can three-times-a-day cyclosporine Neoral avoid cyclosporine toxicity in renal transplant recipients? A pharmacokinetic study.
    Swart N; Botha J; Tandon V; Michaels P; Pontin AR; Halkett J; Pascoe MD; Kahn D
    Transplant Proc; 2001; 33(7-8):3140-1. PubMed ID: 11750349
    [No Abstract]   [Full Text] [Related]  

  • 11. Induction therapy with bolus ATG increases cyclosporine sensitivity in renal transplant recipients.
    Varghese Z; Abudher MN; Fernando ON; Moorhead JF
    Transplant Proc; 2001 May; 33(3):2251-3. PubMed ID: 11377518
    [No Abstract]   [Full Text] [Related]  

  • 12. A quality of life comparison in cyclosporine- and tacrolimus-treated renal transplant recipients across Canada.
    Prasad GV; Nash MM; Keough-Ryan T; Shapiro RJ
    J Nephrol; 2010; 23(3):274-81. PubMed ID: 20383867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conversion from cyclosporine to tacrolimus prevents transplant function loss due to acute steroid-resistant or chronic rejection in renal allograft recipients.
    Blume C; Hollenbeck M; Ivens K; Heering P; Hetzel GR; Grabensee B
    Transplant Proc; 2001; 33(7-8):3161-3. PubMed ID: 11750357
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical safety and tolerability of microemulsion cyclosporine in stable renal transplant patients.
    Gracida C; Melchor JL
    Transplant Proc; 1996 Dec; 28(6):3379. PubMed ID: 8962318
    [No Abstract]   [Full Text] [Related]  

  • 15. Lipid profile in renal transplant recipients under various immunosuppressive regimens.
    Montagnino G; Tarantino A; Aroldi A; Banfi G; Cesana B; Ponticelli C
    Transplant Proc; 1994 Oct; 26(5):2634-6. PubMed ID: 7940821
    [No Abstract]   [Full Text] [Related]  

  • 16. Safety, tolerability, and pharmacokinetics of Sandimmun Neoral: conversion study in stable renal transplant recipients.
    Tsang WK; Ho YW; Tong KL; Chan WH; Chan A
    Transplant Proc; 1996 Jun; 28(3):1330-2. PubMed ID: 8658681
    [No Abstract]   [Full Text] [Related]  

  • 17. Compliance with cyclosporine in adolescent renal transplant recipients.
    Blowey DL; Hébert D; Arbus GS; Pool R; Korus M; Koren G
    Pediatr Nephrol; 1997 Oct; 11(5):547-51. PubMed ID: 9323277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A numerical scale comparison of renal transplant recipient experience with and opinions about calcineurin inhibitors.
    Prasad GV; Nash MM; McFarlane PA; Zaltzman JS
    Nephron Clin Pract; 2004; 97(2):c35-40. PubMed ID: 15218328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conversion from cyclosporine to tacrolimus in kidney, kidney/pancreas, and pancreas alone transplant recipients: the Memphis experience.
    Alloway RR; Russell WC; Gaber LW; Amiri MH; Vera SR; Gaber AO
    Transplant Proc; 1996 Apr; 28(2):995-7. PubMed ID: 8623494
    [No Abstract]   [Full Text] [Related]  

  • 20. Conventional versus Neoral cyclosporine in renal transplantation.
    Rovelli E; Bucci A; Maldifassi P; Belfiore A; D'Amico G
    Transplant Proc; 1998 Aug; 30(5):1764-5. PubMed ID: 9723272
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.